Trius Therapeutics Reviews

4.1
Recommend to a friend
Approve of CEO
Trius Therapeutics President, CEO, and Director Jeffrey Stein
Jeffrey Stein
1 Rating
  • Successful infectious disease company

    • Work/Life Balance
    • Culture & Values
    • Career Opportunities
    • Comp & Benefits
    • Senior Management
    Former Employee - Anonymous Employee in San Diego, CA
    Former Employee - Anonymous Employee in San Diego, CA

    I worked at Trius Therapeutics full-time (More than a year)

    Recommends
    Neutral Outlook
    No opinion of CEO
    Recommends
    Neutral Outlook
    No opinion of CEO

    Pros

    Great opportunity for proactive, highly motivated employees

    Cons

    Recent layoffs due to acquisition


Trius Therapeutics Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.triusrx.com
Headquarters San Diego, CA
Size 50 to 149 Employees
Founded Unknown
Type Company - Public
Industry Biotech & Pharmaceuticals
Revenue $10 to $25 million (USD) per year
Competitors Abbott Labs, Pfizer, Astellas

Trius Therapeutics is an early-stage biopharmaceutical company developing antibiotics to treat life-threatening bacterial infections. Torezolid phosphate, its lead candidate, is an IV- and orally-administered antibiotic being studied for its potential to treat antibiotic-resistant strains of staph infection, known as MRSA (methicillin-resistant Staphylococcus aureus). The company will market torezolid phosphate to hospitals and other health care providers if and when it is approved by the FDA. Trius went public in 2010 through an IPO worth about $50 million. The company... More

Work at Trius Therapeutics? Share Your Experiences

Trius Therapeutics

 
Click to Rate
or